arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Minerva Neurosciences, Inc.

NERV
$2.29 ▼ -0.24 (-9.49%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Minerva Neurosciences, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $19.4M
Dividend Yield —
Revenue Growth —
Op. Margin None
ROIC 8.5% ↘
FCF / Share $-1.60 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-293.42M
↓ -20492.7% —
FCF / Share Free cash flow per share
$-1.60
↑ +38.2% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns ↑
100
Cash Quality ↓
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 55 quarters